Sickle Cell Trait, Sickle Cell Disease, and Fertility

Sickle cell conditions affect an estimated 100,000 Americans and millions of people worldwide, yet fertility discussions around these diagnoses remain rare. Whether you carry sickle cell trait or live with sickle cell disease, understanding how these conditions interact with conception and pregnancy is a necessary part of family planning.

The distinction between trait and disease matters enormously for reproductive outcomes. This guide separates the two, maps the fertility implications of each, and outlines the conversations worth having before you start trying.

Trait vs. Disease: Why the Distinction Matters

Sickle cell trait (SCT) means carrying one copy of the hemoglobin S gene. Sickle cell disease (SCD) means carrying two copies (or one S plus another variant like C or beta-thalassemia). The reproductive implications are different in kind, not just degree.

How Sickle Cell Disease Affects Female Fertility

Women with SCD face several reproductive challenges that compound over time. Chronic hemolytic anemia can disrupt the hypothalamic-pituitary-ovarian axis, leading to delayed puberty, irregular cycles, or anovulation. Recurrent vaso-occlusive episodes affecting the ovaries may reduce ovarian reserve earlier than expected.

Iron overload from repeated transfusions can deposit in the pituitary gland and ovaries, further suppressing reproductive hormones. Studies suggest that women with SCD reach menopause earlier on average and may have lower AMH levels than age-matched controls.

How Sickle Cell Disease Affects Male Fertility

The impact on men with SCD is significant and underrecognized. Testicular infarction from sickling can damage sperm-producing tissue over time. Priapism, which affects roughly 35% of males with SCD, can cause erectile tissue scarring that leads to erectile dysfunction.

Hydroxyurea, the most commonly prescribed disease-modifying therapy, has been associated with reduced sperm counts in some studies, though the evidence is mixed. Men on hydroxyurea who are planning conception should discuss timing and alternatives with both their hematologist and a reproductive urologist.

Genetic Counseling and Carrier Screening

The conversation about genetics should happen before conception, not during pregnancy. The math is straightforward:

• If one partner has trait and the other does not carry any variant: no child will have SCD, though some may carry trait
• If both partners carry trait: each pregnancy has a 25% chance of SCD, 50% chance of trait, and 25% chance of being unaffected
• If one partner has disease and the other carries trait: each pregnancy has a 50% chance of SCD

Expanded carrier screening panels offered by most fertility clinics now test for sickle cell variants alongside hundreds of other conditions. A hemoglobin electrophoresis is the standard standalone test.

IVF with PGT-M: Reducing the Risk

For couples where both partners carry sickle cell variants, preimplantation genetic testing for monogenic conditions (PGT-M) offers a path forward. Embryos created through IVF are biopsied at the blastocyst stage, and only those without two disease-causing variants are transferred.

PGT-M requires advance setup: the testing laboratory needs DNA samples from both partners (and sometimes family members) to build a custom probe. This process, called "workup," typically takes 4 to 8 weeks and should be initiated before starting an IVF cycle.

Pregnancy Planning with SCD

Women with SCD who become pregnant face elevated risks of preeclampsia, placental abruption, fetal growth restriction, and preterm delivery. Pain crises may increase in frequency during pregnancy. None of this means pregnancy is inadvisable, but it does mean a maternal-fetal medicine specialist (MFM) should be involved from the start.

Medication reviews are critical. Hydroxyurea is typically discontinued before conception due to potential teratogenicity. ACE inhibitors, sometimes used for SCD-related nephropathy, are contraindicated in pregnancy. Iron chelation therapy requires reassessment. Each of these transitions should be managed deliberately, not discovered after a positive test.

What to Bring Up at Your First Visit

If sickle cell is part of your health picture and you are planning a family, these questions are worth raising early:

• Has my partner been screened for hemoglobin variants?
• Should we consider PGT-M, and how long does the probe workup take?
• What is my current ovarian reserve, and has my disease affected it?
• How should we time medication changes around conception attempts?
• Which specialists need to be on my pregnancy team from day one?